Chyl-Surdacka Katarzyna Maria, Bartosińska Joanna, Kowal Małgorzata, Przepiórka-Kosińska Joanna, Krasowska Dorota, Chodorowska Grażyna
Department of Dermatology, Venerology and Paediatric Dermatology, Medical University of Lublin, Poland.
Adv Clin Exp Med. 2020 Jan;29(1):79-84. doi: 10.17219/acem/111820.
Visfatin is one of the pro-inflammatory adipokines secreted by adipose tissue cells. Recent scientific research has drawn attention to the role of adipokines in the pathophysiology of metabolic disorders and their association with inflammatory diseases, including psoriasis. Visfatin may be one of the important links explaining the connection between psoriasis and diseases which are components of metabolic syndrome.
The aim of this study was to assess the serum visfatin concentration in patients with psoriasis and to evaluate its possible correlations with parameters of metabolic syndrome and the clinical severity of psoriasis.
A group of 102 patients with psoriasis and a control group of 40 healthy subjects were examined. The clinical severity of psoriasis was assessed according to Psoriasis Area and Severity Index), BSA (Body Surface Area) and DLQI (Dermatology Life Quality Index) indicators, the presence and type of obesity, and hypertension. In both the study and control groups, laboratory tests (C-reactive protein (CRP), glucose concentration, total cholesterol, low-density-lipoprotein (LDL) cholesterol, high-density-lipoprotein (HDL) cholesterol, and triglycerides (TG)) were performed and serum visfatin concentrations were determined. The clinical data, results of laboratory tests and visfatin concentrations were then subjected to statistical analysis.
There was a significantly higher concentration of visfatin in the psoriatic patients (p < 0.001) than in the control group. Significant positive correlations between visfatin concentration and PASI (p = 0.008) and BSA (p = 0.007) were observed. In the psoriatic group, there were positive correlations between the concentrations of visfatin and the concentrations of CRP (p = 0.008) and total cholesterol (p = 0.002). Visfatin concentration was elevated in the psoriatic patients who had elevated total cholesterol (p = 0.001), LDL cholesterol (p = 0.012) and TG levels (p = 0.001) compared to the psoriatic patients with normal levels of these lipid profile components.
The results indicate the possible participation of visfatin in pathophysiological and inflammatory processes in the course of psoriasis. Adipokines may be an important link connecting psoriasis with coexisting metabolic disorders.
内脂素是脂肪组织细胞分泌的促炎脂肪因子之一。最近的科学研究已将注意力集中在脂肪因子在代谢紊乱病理生理学中的作用及其与包括银屑病在内的炎症性疾病的关联上。内脂素可能是解释银屑病与代谢综合征组成疾病之间联系的重要环节之一。
本研究旨在评估银屑病患者的血清内脂素浓度，并评估其与代谢综合征参数及银屑病临床严重程度的可能相关性。
对102例银屑病患者和40名健康受试者组成的对照组进行检查。根据银屑病面积和严重程度指数、体表面积和皮肤病生活质量指数评估银屑病的临床严重程度，以及肥胖和高血压的存在情况及类型。在研究组和对照组中，均进行了实验室检查（C反应蛋白、血糖浓度、总胆固醇、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇和甘油三酯）并测定血清内脂素浓度。然后对临床数据、实验室检查结果和内脂素浓度进行统计分析。
银屑病患者体内内脂素浓度显著高于对照组（p < 0.001）。观察到内脂素浓度与银屑病面积和严重程度指数（p = 0.008）及体表面积（p = 0.007）之间存在显著正相关。在银屑病组中，内脂素浓度与C反应蛋白浓度（p = 0.008）和总胆固醇浓度（p = 0.002）之间存在正相关。与这些血脂成分水平正常的银屑病患者相比，总胆固醇（p = 0.001）、低密度脂蛋白胆固醇（p = 0.012）和甘油三酯水平（p = 0.001）升高的银屑病患者体内内脂素浓度升高。
结果表明内脂素可能参与了银屑病病程中的病理生理和炎症过程。脂肪因子可能是连接银屑病与并存代谢紊乱的重要环节。
